Luis Diaz - 24 Jun 2022 Form 4 Insider Report for Jounce Therapeutics, Inc. (JNCE)

Role
Director
Signature
/s/ Caroline Gammill, Attorney-in-fact
Issuer symbol
JNCE
Transactions as of
24 Jun 2022
Net transactions value
$0
Form type
4
Filing time
28 Jun 2022, 21:00:34 UTC
Previous filing
22 Jun 2021
Next filing
04 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNCE Stock Option (Right to Buy) Award $0 +20,000 $0.000000 20,000 24 Jun 2022 Common Stock 20,000 $2.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2023 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors.

Remarks:

Exhibit 24- Limited Power of Attorney